Skip to main content
. 2016 Mar 8;17(4):407–413. doi: 10.1080/15384047.2016.1156256

Figure 2.

Figure 2.

Overall survival curves. (A) The OS of patients without EGFR mutation is significantly longer than that with EGFR mutation. (B) The OS of patients with low PD-L1 in tumor is significantly longer than that with high PD-L1. (C) The OS of patients with tumor size of T1/2 is significantly longer than that with tumor size of T3/4. (D) The OS of patients without lymph node metastasis is significantly longer than that with lymph node metastasis. Fig 1.